latest news releases from the newsroom
Wilshire Bancorp, Inc.
Wilshire Bancorp Earns $6.9 Million, or $0.23 Per Diluted Share in Third Quarter, Credit Metrics Remain Strong and Interest Margins Expand
LOS ANGELES, Oct. 21, 2008 (GLOBE NEWSWIRE) -- Wilshire Bancorp, Inc. (Nasdaq:WIBC), the holding company for Wilshire State Bank, today reported that net income increased 3% to $6.9 million, or $0.23 per diluted share, in the third quarter of 2008 compared with $6.6 million, or $0.23 per diluted share, in the third quarter a year ago. Net interest margin increased 8 basis points to 3.86% at September 30, 2008 from 3.78% at June 30, 2008. Allowance for loan losses to gross loans ratio increased to 1.28% at September 30, 2008, as compared with 1.18% at June 30, 2008 and 1.21% at September 30, 2007.
Avigen Announces AV650 Did Not Meet Efficacy Endpoints in Phase 2b Clinical Trial for Spasticity in Patients With Multiple Sclerosis
ALAMEDA, Calif., Oct. 21, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today announced that the top-line data from its Phase 2b study of AV650 (tolperisone HCl) for the treatment of spasticity associated with multiple sclerosis (MS) did not achieve statistical significance on its primary endpoint of a reduction from baseline of patients' Ashworth scores as compared to placebo. The reduction of muscle spasm, a secondary endpoint, also failed to achieve statistical significance. There were no safety issues. The trial was adequately powered, and all statistical parameters were in line with expectations.
Pharsight Initiates Beta Testing of New Advanced Platform for Modeling Software Products
MOUNTAIN VIEW, Calif., Oct. 21, 2008 (GLOBE NEWSWIRE) -- Pharsight Corporation (Nasdaq:PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that is has initiated beta testing of its new Phoenix(tm) analysis and modeling software platform. The beta program covers a new, Phoenix-compatible version of WinNonlin(r), Pharsight's industry-standard pharmacokinetic and pharmacodynamic (PK/PD) modeling and analysis tool. In addition to Phoenix(tm) WinNonlin(r), the beta program also covers new population modeling tools currently under development by Pharsight.